Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 6/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL28097171 | 1.00 | KDM4E (0.52) | KDM4EALDH1A1TDP1CYP1A2TP53 | |
| Bromide SCHEMBL28298659 | 0.98 | KDM4E (0.50) | KDM4EALDH1A1TDP1CYP1A2TP53 | |
| Bromide SCHEMBL27697911 | 0.98 | KDM4E (0.50) | KDM4EALDH1A1TDP1CYP1A2TP53 | |
| Bromide SCHEMBL28903213 | 0.98 | KDM4E (0.50) | KDM4EALDH1A1TDP1CYP1A2TP53 | |
| Bromide SCHEMBL653935 | 0.98 | CHRNA7 (0.50) | KDM4EALDH1A1TDP1CYP1A2TP53 | |
| Bromide SCHEMBL27715865 | 0.98 | KDM4E (0.50) | KDM4EALDH1A1TDP1CYP1A2TP53 | |
| Bromide SCHEMBL3641373 | 0.98 | KDM4E (0.50) | KDM4EALDH1A1TDP1CYP1A2TP53 | |
| SCHEMBL81238 | 0.97 | KDM4E (0.54) | KDM4EALDH1A1TDP1CYP1A2TP53 | |
| Hydrogen Sulfide SCHEMBL5998579 | 0.97 | KDM4E (0.54) | KDM4EALDH1A1TDP1CYP1A2TP53 | |
| Benzene SCHEMBL29130108 | 0.97 | KDM4E (0.54) | KDM4EALDH1A1TDP1CYP1A2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114166921-B | Application of chloramine derivatization reagent in double bond position identification | 中国科学院上海有机化学研究所 | 2024-04-26 | — | — | CN | claimed |
| CN-109836425-B | Preparation process of synthetic pemetrexed | 江苏创诺制药有限公司 | 2023-01-24 | — | — | CN | claimed |
| CN-109836425-B | Preparation process of synthetic pemetrexed | 江苏创诺制药有限公司 | 2023-01-24 | — | — | CN | disclosed |
| CN-112980046-B | Special high-thermal-stability flame retardant for EPS/XPS and preparation method thereof | 山东润科化工股份有限公司 | 2022-04-19 | — | — | CN | disclosed |
| CN-107785179-B | Preparation method of bromide capacitor positive plate | 横店集团东磁股份有限公司 | 2020-09-29 | — | — | CN | disclosed |
| CN-107785177-B | Bromide capacitor positive electrode slurry and preparation method thereof | 横店集团东磁股份有限公司 | 2020-09-22 | — | — | CN | disclosed |
| CN-107799768-B | Bromide cylindrical battery and assembling method thereof | 横店集团东磁股份有限公司 | 2020-07-31 | — | — | CN | disclosed |
| CN-107785572-B | Bromide square battery and assembling method thereof | 横店集团东磁股份有限公司 | 2020-07-28 | — | — | CN | disclosed |
| CN-107799766-B | Bromide soft package battery and assembling method thereof | 横店集团东磁股份有限公司 | 2020-07-28 | — | — | CN | disclosed |
| CN-107666008-B | Bromide battery positive plate and preparation method thereof | 横店集团东磁股份有限公司 | 2020-07-17 | — | — | CN | disclosed |
| US-8119808-B2 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-21 | — | — | US | disclosed |
| EP-1644335-A4 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2008-06-04 | — | — | EP | disclosed |
| EP-1885709-A2 | BENZOFURAN DERIVATIVES WITH THERAPEUTIC ACTIVITIES | Pharmos Corporation (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20070099950-A1 | Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain | AGT SCIENCE LIMITED (GB) | 2007-05-03 | — | — | US | disclosed |
| WO-2006129318-A2 | BENZOFURAN DERIVATIVES WITH THERAPEUTIC ACTIVITIES | PHARMOS CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| EP-1687275-A1 | PYRIDIN-4-YLAMINE COMPOUNDS USEFUL IN THE TREATMENT OF NEUROPATHIC PAIN | Merck & Co., Inc. (US) | 2006-08-09 | — | — | EP | disclosed |
| EP-1644335-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005051915-A1 | PYRIDIN-4-YLAMINE COMPOUNDS USEFUL IN THE TREATMENT OF NEUROPATHIC PAIN | MERCK & CO., INC. (US) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005007628-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20050014786-A1 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014786-A1 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | CNR2, CNR1, OPRL1 | ACHE 771/4885KDM4E 612/4885ALDH1A1 3577/4885 |
| US-20070099950-A1 | Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain | PER2, CNR2, OPRD1 | ACHE 988/4885KDM4E 699/4885ALDH1A1 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.